NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)

NCI 社区肿瘤​​学研究计划 (NCORP) 社区站点（需要 UG1 临床试验）

• 批准号: 10673178
• 负责人: Judith O Hopkins
• 金额: $ 225.87万
• 依托单位: SOUTHEAST CLINICAL ONCOL RES CONSORTIUM
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673178
• 关键词: Acceleration; Advocate; Aftercare; Appalachian Region; Area; Cancer Control; Caregivers; Caring; Catchment Area; Clinical; Clinical Oncology; Clinical Research; Clinical Trials; Communities; Community Clinical Oncology Program; Community Hospitals; Development; Education; Emergency Medicine; Ensure; Ethnic Origin; Evidence Based Medicine; Evidence based practice; Florida; Funding; Gastroenterology; Geographic Locations; Geographic state; Goals; Gynecology; Health; Hospitals; Infrastructure; Leadership; Malignant Neoplasms; Mentors; Minority Groups; Monitor; National Cancer Institute; National Clinical Trials Network; North Carolina; Oncology; Operative Surgical Procedures; Outcome; Palliative Care; Participant; Patients; Persons; Population; Preparation; Prevention; Primary Care; Principal Investigator; Private Practice; Quality of Care; Quality of life; Radiology Specialty; Research; Research Institute; Research Personnel; Rural; Scientific Advances and Accomplishments; Site; Site Visit; South Carolina; System; Tennessee; Training; Underserved Population; Urology; Virginia; age group; base; cancer care; cancer health disparity; cancer therapy; care delivery; clinical imaging; community organizations; data submission; design; experience; health care delivery; health care disparity; human subject protection; improved; innovation; medically underserved; medically underserved population; member; metropolitan; next generation; operation; patient population; performance site; precision medicine; programs; recruit; research study; rural underserved; screening; targeted treatment

SCOR Project Summary/Abstract The Southeast Clinical Oncology Research Consortium (SCOR) is a unique organization comprised of 21 community members from rural and metropolitan areas under the leadership of three experienced Principal Investigators (PIs), a Leadership Council, and the SCOR Operations Center (SOC). The members comprise small community hospitals, hospital systems, and private practices in a six-state geographical area (Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia). The primary goal of this application is to bring NCI clinical trials and Cancer Care Delivery Research (CCDR) to the catchment area. A second goal is to facilitate the use of effective, evidence-based practices to improve the quality of care, health outcomes, and reduce cancer health care disparities. There are currently 230 investigators and 160 clinical research staff across 93 treatment performance sites engaged in National Cancer Institute (NCI) research. Each community has a Community Responsible Investigator to oversee research and to ensure human subjects protection. SCOR has a Young Investigator Mentoring Program designed to increase participation of the next generation of NCI investigators in cancer clinical research. Each community also has a research coordinator who is responsible for clinical operations. The SCOR catchment area includes over 16 million people with significant ethnic, rural, and medically underserved populations. The SOC in Winston-Salem, NC provides extensive expertise, regulatory assistance, training, monitoring, mentoring, education, and coordination to facilitate member community’s ability to provide clinical trials to their patient population. SOC staff conducts at least yearly site visits to each community member to review their research program and recruitment strategies, to ensure compliance and quality data submission, and to assist with audit preparation. This infrastructure allows understaffed member communities to conduct NCI clinical research. The efficient, centralized SOC and experienced PI leadership will facilitate accomplishment of the goals of this application.

SCOR项目摘要/摘要 东南临床肿瘤学研究联盟(SCOR)是一个独特的组织 由21名来自农村和大都市地区的社区成员组成，由 三名经验丰富的首席调查员(PI)、一个领导委员会和SCOR 运营中心(SOC)。成员包括小型社区医院、医院系统、 在六个州的地理区域(佛罗里达州、佐治亚州、北卡罗来纳州、南卡罗来纳州)和私人诊所 卡罗莱纳州、田纳西州和弗吉尼亚州)。该应用程序的主要目标是将NCI临床 试验和癌症护理提供研究(CCDR)到集水区。第二个目标是 促进使用有效的、循证的做法，以提高护理、保健和保健的质量 结果，并减少癌症医疗保健差距。目前有230名调查人员和 在93个治疗绩效站点从事国家癌症工作的160名临床研究人员 研究所(NCI)研究。每个社区都有一名社区责任调查员负责监督 研究并确保人类受试者的保护。SCOR有一位年轻的调查员指导 旨在增加下一代NCI癌症研究人员参与的计划 临床研究。每个社区也有一名研究协调员，负责 临床手术。南海走廊的集水区包括1600多万人，他们有重要的 种族、农村和医疗服务不足的人群。北卡罗来纳州温斯顿-塞勒姆的SOC提供 广泛的专业知识、监管援助、培训、监控、指导、教育和 协调以促进成员社区向其患者提供临床试验的能力 人口。SOC工作人员至少每年对每个社区成员进行现场访问以进行审查 他们的研究计划和招聘战略，以确保合规和高质量的数据 提交，并协助准备审计。此基础设施允许人员不足的成员 社区开展NCI临床研究。高效、集中的SOC和经验丰富的 PI领导力将促进本应用程序目标的实现。

项目成果

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.

• DOI: 10.1200/jco.22.00912
• 发表时间: 2022-07-20
• 期刊: JOURNAL OF CLINICAL ONCOLOGY
• 影响因子: 45.3
• 作者: Reckamp, Karen L.;Redman, Mary W.;Dragnev, Konstantin H.;Minichiello, Katherine;Villaruz, Liza C.;Faller, Bryan;Al Baghdadi, Tareq;Hines, Susan;Everhart, Leah;Highleyman, Louise;Papadimitrakopoulou, Vassiliki;Gandara, David R.;Kelly, Karen;Herbst, Roy S.
• 通讯作者: Herbst, Roy S.

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

• DOI: 10.1016/j.cllc.2020.09.013
• 发表时间: 2021-05
• 期刊: Clinical lung cancer
• 影响因子: 3.6
• 作者: Waqar SN;Redman MW;Arnold SM;Hirsch FR;Mack PC;Schwartz LH;Gandara DR;Stinchcombe TE;Leighl NB;Ramalingam SS;Tanna SH;Raddin RS;Minichiello K;Bradley JD;Kelly K;Herbst RS;Papadimitrakopoulou VA
• 通讯作者: Papadimitrakopoulou VA

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.

palbociclib（PD-0332991）在CCND1、2或3扩增中的II期研究：NCI匹配ECOG-ACRIN试验（EAY131）子协议Z1B的结果。

• DOI: 10.1158/1078-0432.ccr-22-2150
• 发表时间: 2023-04-14
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405.

CALGB转移性结直肠癌的体重指数和体重减轻（联盟）/SWOG 80405。

• DOI: 10.1093/jncics/pkaa024
• 发表时间: 2020-06
• 期刊: JNCI cancer spectrum
• 影响因子: 4.4
• 作者: Guercio BJ;Zhang S;Venook AP;Ou FS;Niedzwiecki D;Lenz HJ;Innocenti F;Mullen BC;O'Neil BH;Shaw JE;Polite BN;Hochster HS;Atkins JN;Goldberg RM;Brown JC;O'Reilly EM;Mayer RJ;Blanke CD;Fuchs CS;Meyerhardt JA
• 通讯作者: Meyerhardt JA

Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.

与 II-III 期结肠癌患者生存相关的遗传变异。

• DOI: 10.1016/j.cgh.2019.11.046
• 发表时间: 2020
• 期刊: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
• 作者: Penney,KathrynL;Banbury,BarbaraL;Bien,Stephanie;Harrison,TabithaA;Hua,Xinwei;Phipps,AmandaI;Sun,Wei;Song,Mingyang;Joshi,AmitD;Alberts,StevenR;Allegra,CarmenJ;Atkins,James;Colangelo,LindaH;George,ThomasJ;Goldberg,Richa
• 通讯作者: Goldberg,Richa